Benzimidazole derivatives are providing having the structure ##STR1## wherein R1 is lower alkyl, phenyl-lower alkyl, halo-lower alkyl, mono-lower alkylaminoalkyl, di-lower alkylaminoalkyl, and alkyl pyridinium halide, R2 and R3 may be the same or different and are hydrogen or lower alkyl, R4 is cycloalkyl or cycloalkenyl, and m is 0 to 3, n is 0 to 3, m + n being ≦5. These compounds are useful as anthelmintic agents.
|
1. A compound of the structure ##STR53## wherein R1 is lower alkyl, phenyl-lower alkyl, halo-lower alkyl, mono lower alkylaminoalkyl, and alkyl pyridinium halide, R2 and R3 are the same or different and are selected from the group consisting of hydrogen or lower alkyl, and R4 is cycloalkyl containing 3 to 12 carbons or cycloalkenyl containing 3 to 10 carbons, m is 0 to 3, n is 0 to 3 and m + n is ≦ 5, and physiologically acceptable salts thereof where R1 includes an amino function.
5. The compound as defined in
6. The compound as defined in
7. The compound as defined in
8. The compound as defined in
9. A pharmaceutical composition for use in treating helminthiasis comprising a therapeutically effective amount of a compound as defined in
10. A method for treating helminthiasis which comprises administering to a mammalian host a therapeutically effective amount of the composition as defined in
|
|||||||||||||||||||||||||||||||||||||||||
The present invention relates to benzimidazole derivatives having the structure ##STR2## wherein R1 is lower alkyl, phenyl-lower alkyl, halo-lower alkyl, mono-lower alkylaminoalkyl, di-lower alkylaminoalkyl, and alkyl pyridinium halide R2 and R3 may be the same or different and are hydrogen or lower alkyl, and R4 is cycloalkyl or cycloalkenyl, m is 0 to 3, n is 0 to 3 and m + n is ≦ 5.
The term "halogen" or "halo" as used throughout the specification refers to fluorine, chlorine, bromine, and iodine; chlorine is preferred.
The term "lower alkyl" as used herein includes straight or branched chain aliphatic hydrocarbon radicals having up to and including seven carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, amyl, hexyl, heptyl and the like.
(CH2)m and (CH2)n represent a single bond or straight or branched chain alkylene radicals containing 3 or less carbons in the longest normal chain.
The term "alkyl pyridinium halide" refers to a radical of the structure ##STR3## wherein (CH2)n, represents a straight or branched chain alkyl radical containing from 2 to 5 carbons in the longest normal chain and X is Cl or Br.
The term "phenyl lower alkyl" as used herein refers to lower alkyl groups as discussed above having a phenyl substituent, such as benzyl.
The term "cycloalkyl" includes cyclic hydrocarbon groups containing 3 to 12 carbons, while the term "cycloalkenyl" includes cyclic hydrocarbon groups containing 3 to 10 carbons. Examples of suitable cycloalkyl and cycloalkenyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cycloedecyl and cyclododecyl, cyclopropenyl, cyclobutenyl, cyclohexenyl, cycloheptenyl, cyclononeyl and cyclodecenyl, any of which groups may be substituted with 1, 2, 3 or 4 halogen or lower alkyl groups. In the above cycloalkenyl rings, the double bond may be at any position in the ring.
Preferred are those compounds wherein R1 is methyl, ethyl, propyl or benzyl, or dimethylaminopropyl, m is 0, n is 0, R2 is hydrogen, R3 is hydrogen or methyl, R4 is cyclopropyl, cyclohexyl, cyclooctyl, 2,2-dichlorocyclopropyl or cyclohexen-3-yl.
Examples of preferred compounds falling within the present invention include the following.
| __________________________________________________________________________ |
| ##STR4## |
| R1 R2 |
| R3 |
| R4 (CH2)m |
| (CH2)n |
| __________________________________________________________________________ |
| 1. |
| CH3 H H |
| ##STR5## |
| -- -- |
| 2. |
| CH3 H H |
| ##STR6## |
| -- -- |
| 3. |
| CH3 H H |
| ##STR7## |
| -- -- |
| 4. |
| C2 H5 |
| CH3 |
| H |
| ##STR8## |
| -- -- |
| 5. |
| CH3 H H |
| ##STR9## |
| -- -- |
| 6. |
| C6 H5 CH2 |
| H H |
| ##STR10## |
| -- -- |
| 7. |
| C3 H7 |
| H H |
| ##STR11## |
| -- -- |
| 8. |
| CH3 H H |
| ##STR12## |
| -- -- |
| 9. |
| C6 H5 CH2 |
| H H |
| ##STR13## |
| -- -- |
| 10. |
| C3 H7 |
| H H |
| ##STR14## |
| -- -- |
| (CH3)2 NC2 H4 |
| H C2 H5 |
| ##STR15## |
| CH2 |
| -- |
| C2 H5 NHC3 H6 |
| H H |
| ##STR16## |
| -- CH2 |
| ClC3 H6 |
| CH3 |
| CH3 |
| ##STR17## |
| CH2 |
| CH2 |
| ##STR18## H H |
| ##STR19## |
| -- -- |
| __________________________________________________________________________ |
The benzimidazole derivatives of structure I may be prepared by thiocyanation of o-nitroaniline to yield 4-thiocyano-2-nitroaniline (II). This product is then subjected to a sodium borohydride reduction to yield the corresponding 4-mercapto-2-nitroaniline (III). The mercapto derivative may be isolated or used directly for the next step. Thus, to the reaction mixture there is added the haloalkyl cycloalkane or haloalkyl cycloalkene IV to furnish the sulfide V. ##STR20##
Examples of suitable haloalkyl cycloalkanes and haloalkyl cycloalkenes of formula IV suitable for use herein include the following: ##STR21## The resulting sulfides may be purified by crystallization and then reduced to the corresponding o-phenylene diamine VI. Either chemical or catalytic reduction may be used. For the chemical reduction the procedure outlined by Sandler and Caro (Organic Functional Group Preparations, 1968, pp 339-340) is preferred. The final step in the synthesis of I, namely ring closure of VI to furnish I, can be achieved in various ways. Whereas refluxing of VI with the isolated thiourea derivative VII in alcohols such as methanol or ethanol will furnish I, the preferred method of preparing I is by forming VII in situ and then without isolating it adding VI and refluxing it for 30 minutes to 5 hours to yield the desired product. ##STR22##
An alternative route toward the intermediate VI offers the reaction of VIII with the requisite mercaptoalkyl cycloalkane or cycloalkene IX, to yield X. Here, in contrast to the alkylation step described above, (i.e., IV → V) the reaction temperature has to be higher and the reaction periods have to be longer. Reduction of X yields the desired diamine VI ##STR23##
A great variety of haloalkyl cycloalkanes IV are commercially available. In some cases the requisite haloalkyl cycloalkane has to be synthesized. For example, the addition of dichlorocarbene to allyl bromide furnishes the cyclopropyl derivative IV ##STR24##
Additions of other than dichlorocarbene are possible, such as, monochlorocarbene, dibromocarbene, and the like. ##STR25##
The requisite haloalkyl cycloalkanes or cycloalkenes may also be prepared from the corresponding alcohols by standard reactions.
In certain instances, the compounds of formula I form physiologically acceptable acid-addition salts with inorganic and organic acids, for example, where R1 contains an amino function as indicated above. These salts frequently provide useful means for isolating the products from reaction mixtures by forming the salt in a medium in which it is insoluble. The free base may then be obtained by neutralization. Then any other salt may again be formed from the free base and the appropriate inorganic acid. Illustrative are the hydrohalides, especially the hydrochloride and hydrobromide which are preferred, sulfate, nitrate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, and the like.
The compounds of formula I have anthelmintic activity and are useful in the treatment and/or prevention of helminthiasis, a parasitic disease which causes widespread and often serious infection in domesticated animals such as swine, horses, cattle, dogs, cats and sheep. The compounds are useful in treating infections caused by Haemonchus, Ostertagia, Trichostrongylus, Cooperia, dictyocaulus, Nematodirus, Bunostomum, Strongyloides, Oesophagostomum, Trichiuris and Moniezia. In treating domesticated animals, the compounds are given orally; however, other routes such as subcutaneously may be employed. Where the compounds are administered orally, they may be mixed with a nontoxic, edible carrier to form a feed supplement, or be administered in unit dosage forms such as powders, capsule, tablet, boluses, drenches, etc.
In general, the compound of formula I exhibit anthelmintic activity when administered to animals in a single dose of from about 5 to about 100 mg per kilogram of animal body weight. It is preferred to employ in the range of 5-25 mg per kilogram of body weight. The compounds may be given in a single dose or divided into a plurality of smaller doses.
When the compounds of formula I are to be administered in unit dosage form, capsules, boluses or drenches containing the desired amount of anthelmintic distributed in a pharmaceutically acceptable vehicle are usually employed. These are prepared by intimately and uniformly mixing the active ingredient with suitable finely divided diluents, suspending agents, fillers, disintegrating agents and/or binders such as starch, lactose, talc, magnesium stearate, vegetable gums and the like and are compounded by techniques generally known in the art.
The compounds of formula I may also be administered as a component of the feed of the animals or suspended in the drinking water. Thus, novel feed and feed supplement compositions may be prepared in which the compounds of this invention are present as an active anthelmintic ingredient. A typical feed supplement comprises the anthelmintic agent intimately dispersed in or admixed with an inert carrier or diluent, i.e., one that is nonreactive with respect to the anthelmintic agent and that may be administered with safety to the animals. The carrier or diluent is preferably one that is or may be an ingredient of an animal ration. This composition may be mixed with the feed to give any useful desired concentration, preferably about 0.1-2%. Lastly, feeds containing the active ingredient may be made directly by mixing said active ingredient in a feed which is inert to said anthelmintic compounds so as to give feeds having concentrations of anthelmintic agent of from 0.1-2%.
The following examples are provided for illustrative purposes and may include particular features of the invention, however the examples should not be construed as limiting the invention, many variations of which are possible without departing from the spirit or scope thereof. All temperatures are in degrees centigrade.
PAC 2-Nitro-4-thiocyanoanilineTo a well-stirred mixture of 108 g of o-nitroaniline and 128 g of ammonium thiocyanate in 400 ml of acetic acid there is added dropwise a solution of 128 g of bromine in 160 ml of acetic acid below 20°C The mixture is stirred for 4 hours at room temperature and then poured into 4 liters of water. The resulting solid is filtered off and crystallized from ethanol to yield 86.7 g, m.p. 111°-114°C
PAC 4-(Cyclohexylmethyl)thio-2-nitroanilineTo a stirred mixture of 9.75 g (0.05 mole) of 2-nitro-4-thiocyanoaniline in 500 ml of absolute ethanol under nitrogen there is added 2.04 g (0.05 mole) of sodium borohydride in portions. The mixture is stirred at room temperature for 15 minutes and then refluxed for 15 minutes.
The heating mantle is removed and 3.25 g (0.05 mole) of KOH in 15 ml of absolute ethanol is added. The mixture is stirred for 1 minute. A solution of 8.85 g (0.05 mole) of cyclohexylmethyl bromide in 15 ml of absolute ethanol is added and the mixture is stirred at room temperature for 15 minutes then refluxed for 1 hour. Equal amounts of water and CHCl3 are added until 2 layers are formed. The organic layer is separated, dried (MgSO4) and the solvent removed in vacuo. The residue is crystallized from ethyl ether to yield 8.3 g, m.p. 80°-82°.
PAC 4-(Cyclohexylmethyl)thio-o-phenylenediamineA mixture of 8.0 g (0.03 mole) of 4-(cyclohexylmethyl)thio-2-nitroaniline and 0.5 g of PtO2 in 200 ml of absolute ethanol is reduced on the Parr hydrogenator at 50 psi until the theoretical amount of H2 is absorbed. The mixture is filtered and the solvent is removed in vacuo to yield the solid diamine, m.p. 76°-79°C
PAC [5-[(Cyclohexylmethyl)thio]-1H-benzimidazol-2-yl]carbamic acid, methyl esterTo a mixture of 9 g of 2-methyl-2-thiopseudourea sulfate in 6 ml of water there is added 5.7 ml of methyl chloroformate at 0° C and the mixture is stirred for 15 minutes. Then there is added 12 ml of 25% NaOH dropwise and the mixture is stirred for 15 minutes. Then the total amount of 4-(cyclohexylmethyl)thio-o-phenylenediamine from the above reaction in 50 ml of methanol is added and the mixture is refluxed for 2 hours. The alcohol is removed in vacuo and water is added. The resulting solid is filtered off and crystallized from CH3 CN to yield 2.5 g, m.p. 200°-204°C
PAC 4-(Cyclopropylmethyl)thio-2-nitroanilineTo a stirred mixture of 11.7 g (0.06 mole) of 2-nitro-4-thiocyanoaniline in 500 ml of absolute ethanol under nitrogen there is added 2.5 g (0.06 mole) of sodium borohydride in portions. The mixture is stirred at room temperature for 15 minutes and then refluxed for 15 minutes. The heating mantle is removed and 3.9 g (0.06 mole) of KOH in 25 ml of absolute ethanol is added. The mixture is stirred for 1 minute. A solution of 4.8 g (0.06 mole) of (chloromethyl) cyclopropane in 10 ml of absolute ethanol is added and the mixture is stirred at room temperature for 15 minutes then refluxed for 2 hours. Equal amounts of water and CHCl3 are added until 2 layers are formed. The organic layer is separated, dried (MgSO4), and the solvent removed in vacuo to give 9.1 g of an orange-red solid, m.p. 45°-47°.
PAC 4-(Cyclopropylmethyl)thio-o-phenylenediamineA mixture of 6.75 g (0.03 mole) of 4-(cyclopropylmethyl)thio-2-nitroaniline and 0.5 g of PtO2 in 200 ml of absolute ethanol is reduced on the Parr hydrogenator at 50 psi. The mixture is filtered and the solvent is removed in vacuo to yield the solid diamine, m.p. 57°-60°C
PAC [5-[(Cyclopropylmethyl)thio)-1H-benzimidazol-2-yl]carbamic acid, methyl esterTo a mixture of 9 g of 2-methyl-2-thiopseudourea sulfate in 6 ml of water there is added 5.7 ml of methyl chloroformate at 0° C and the mixture is stirred for 15 minutes. Then there is added 12 ml of 25% NaOH dropwise and the mixture is stirred for 15 minutes. Then there is added 6 ml of acetic acid dropwise and the mixture is stirred for 15 minutes. The total amount of 4-(cyclopropylmethyl)thio-o-phenylenediamine from above in 50 ml of methanol is then added and the mixture is refluxed for 2 hours. The alcohol is removed in vacuo and water is added. The resulting solid is filtrated off and crystallized from glyme-acetonitrile to yield, 3.9 g, m.p. 228°-231°.
PAC [5-[(Cyclopropylmethyl)thio]-1H-benzimidazol-2-yl]carbamic acid, benzyl esterFollowing the procedure of Example 4 and substituting benzyl chloroformate for methyl chloroformate, the title comound is obtained.
PAC [5-[(2,2,3,3-Tetrafluorocyclobutylmethyl)thio]-1H-benzimidazol-2-yl]carbami c acid, methyl esterFollowing the procedures of Examples 5-7 and substituting 1-chloromethyl-2,2,3,3-tetrafluorocyclobutane for cyclohexylmethyl bromide the title compound is obtained.
PAC [5-[(2,2-Dichlorocyclopropylmethyl)thio]-1H-benzimidazol-2-yl]carbamic acid, methyl esterA. 4-[(2,2-dichlorocyclopropyl)methyl]thio-2-nitroaniline
To a stirred mixture of 11.75 g (0.06 mole) of 2-nitro-4-thiocyanoaniline in 500 ml of absolute ethanol under N2 there is added 2.5 g (0.06 mole) of sodium borohydride in portions. The mixture is stirred at room temperature for 15 minutes and then refluxed for 15 minutes. The heating mantle is removed and 3.9 g (0.06 mole) of KOH in 30 ml of absolute ethanol is added. The mixture is stirred for 1 minute. A solution of 12.25 g (0.06 mole) of 1-bromomethyl-2,2-dichlorocyclopropane in 30 ml of absolute ethanol is added and the mixture is stirred at room temperature for 15 minutes and then refluxed for 2 hours. Equal amounts of H2 O and CHCl3 are added until 2 layers are formed. The organic layer is separated, dried (MgSO4), and the solvent removed in vacuo to give a red oil which is chromatographed on silica gel. Elution with ethyl ether gives 9.6 g of red oil.
B. 4-[(2,2-Dichlorocyclopropyl)methyl]thio-o-phenylenediamine
A mixture of 8.8 g (0.03 mole) of 4-[(2,2-dichlorocyclopropyl)methyl]thio-2-nitroaniline and 0.6 g of PtO2 in 200 ml of absolute ethanol is reduced on the Parr hydrogenator at 50 psi until the theoretical amount of H2 is absorbed. The mixture is filtered and the solvent is removed in vacuo to yield a dark oil.
C. [5-[(2,2-Dichlorocyclopropylmethyl)]thio]-1H-benzimidazol-2-yl]carbamic acid, methyl ester
To a mixture of 9 g of 2-methyl-2-thiopseudourea sulfate in 6 ml of H2 O there is added 5.7 ml of methyl chloroformate at 0° C and the mixture is stirred for 15 minutes. Then there is added 12 ml of 25% NaOH dropwise and the mixture is stirred for 15 minutes. Then there is added 6 ml of acetic acid dropwise and the mixture is stirred for 15 minutes. Then the total amount of 4-[(2,2-dichlorocyclopropyl)methyl]thio-o-phenylenediamine from above in 50 ml of methanol is added and the mixture is refluxed for 2 hours. The alcohol is removed in vacuo and H2 O is added. The resulting solid is filtered off and cyystallized from glyme to yield 5.4 g, m.p. 211°-213°.
PAC [5-[(Cyclohexen-3-ylmethyl)thio]-1H-benzimidazol-2-yl]-carbamic acid, 3-dimethylaminopropyl esterA mixture of 0.01 mole of the methyl ester of Example 4 and 0.02 mole of 3-dimethylamino-1-propanol is refluxed in 20 ml of toluene until all the H2 O present has been azeotroped off. The heating mantle is removed and 0.25 g of aluminum isopropoxide is added. The mixture is then refluxed overnight. After cooling the solid present is filtered off, washed with water and crystallized.
Following the procedure of Examples 1 to 4 except substituting for cyclohexylmethyl bromide the compound shown in column I of Table I below and substituting for methyl chloroformate the compound shown in column II, the product shown in column III is obtained.
| TABLE I |
| __________________________________________________________________________ |
| Column I Column II Column III |
| ##STR26## HCOOR1 |
| ##STR27## |
| Ex. No. |
| R4 |
| ##STR28## X |
| R1 |
| ##STR29## R1 |
| __________________________________________________________________________ |
| ##STR30## |
| ##STR31## Cl |
| n-C3 H7 |
| as in Column I as in Column II |
| ##STR32## |
| ##STR33## Br |
| C2 H4 Cl |
| ##STR34## |
| ##STR35## Cl |
| (CH2)4 NHCH3 |
| ##STR36## |
| (CH2)2 |
| Br |
| (CH2)3 N(C2 H5)2 |
| ##STR37## |
| CH2 Cl |
| ##STR38## |
| ##STR39## |
| CH2 Br |
| C2 H5 |
| " " |
| ##STR40## |
| ##STR41## Cl |
| ##STR42## |
| ##STR43## |
| CH2 Br |
| ##STR44## |
| 20. |
| ##STR45## |
| (CH2)2 |
| Cl |
| N(CH3)2 |
| ##STR46## |
| (CH2)2 |
| Br |
| ##STR47## |
| ##STR48## |
| (CH2)2 |
| Cl |
| n-C4 H9 |
| ##STR49## |
| CH2 Br |
| C2 H4 C6 H5 |
| " " |
| ##STR50## |
| ##STR51## Cl |
| CH3 |
| ##STR52## |
| CH2 Br |
| CH3 |
| __________________________________________________________________________ |
Haugwitz, Rudiger D., Maurer, Barbara V.
| Patent | Priority | Assignee | Title |
| 11028055, | Nov 30 2015 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | Compounds for treating proliferative diseases |
| 11697640, | Nov 30 2015 | Children's Medical Center Corporation; Beth Israel Deaconess Medical Center, Inc. | Compounds for treating proliferative diseases |
| 4136174, | Jan 18 1978 | E. R. Squibb & Sons, Inc. | Benzimidazolecarbamates and method |
| 4138493, | Mar 13 1978 | E. R. Squibb & Sons, Inc. | 2,2-Dihalo-1(3)-lower alkyl-cyclopropylalkylthio benzimidazole derivatives, compositions thereof and method of use in treating tapeworms and whipworms |
| 4145433, | Jan 18 1978 | E. R. Squibb & Sons, Inc. | Method of treating helminthiasis by parenteral administration of sulfoxide derivatives of benzimidazoles |
| 4154846, | Jun 16 1978 | E. R. Squibb & Sons, Inc. | Substituted thio-, sulfinyl-, and sulfonyl-alkyl benzimidazole carbamates |
| 4156006, | Jan 09 1978 | E. R. Squibb & Sons, Inc. | Vinyl sulfide derivatives of benzimidazoles |
| 4198422, | May 17 1979 | E. R. Squibb & Sons, Inc. | Substituted 2,3-naphthimidazole carbamates and method |
| 4287199, | Oct 19 1978 | Bayer Aktiengesellschaft | Benzimidazolylcarbamic acid esters substituted on the benzenoid nucleus by an oxy or thio substituent |
| 8293266, | Mar 05 2007 | Huvepharma AD | Paromomycin-supplemented feed stuff for turkey and use thereof for prophylaxis of histomoniasis, reduction of the horizontal spreading of histomoniasis, and for improved weight gain and feed conversion |
| Patent | Priority | Assignee | Title |
| 3929821, | |||
| 3929823, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jul 16 1976 | E. R. Squibb & Sons, Inc. | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Date | Maintenance Schedule |
| Sep 06 1980 | 4 years fee payment window open |
| Mar 06 1981 | 6 months grace period start (w surcharge) |
| Sep 06 1981 | patent expiry (for year 4) |
| Sep 06 1983 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Sep 06 1984 | 8 years fee payment window open |
| Mar 06 1985 | 6 months grace period start (w surcharge) |
| Sep 06 1985 | patent expiry (for year 8) |
| Sep 06 1987 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Sep 06 1988 | 12 years fee payment window open |
| Mar 06 1989 | 6 months grace period start (w surcharge) |
| Sep 06 1989 | patent expiry (for year 12) |
| Sep 06 1991 | 2 years to revive unintentionally abandoned end. (for year 12) |